Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study

详细信息    查看全文

• 作者：Quan Dong Nguyen ; Syed Mahmood Shah ; Jeffery S. Heier ; Diana V. Do ; Jennifer Lim ; David Boyer ; Prema Abraham ; Peter A. Campochiaro ; READ-2 Study Group
• 刊名：Ophthalmology
• 出版年：2009
• 出版时间：November 2009
• 年：2009
• 卷：116
• 期：11
• 页码：2175-2181.e1
• 全文大小：833 K

文摘

Objectives

To compare ranibizumab with focal/grid laser or a combination of both in diabetic macular edema (DME).

Design

Prospective, randomized, interventional, multicenter clinical trial.

Participants

A total of 126 patients with DME.

Methods

Subjects were randomized 1:1:1 to receive 0.5 mg of ranibizumab at baseline and months 1, 3, and 5 (group 1, 42 patients), focal/grid laser photocoagulation at baseline and month 3 if needed (group 2, 42 patients), or a combination of 0.5 mg of ranibizumab and focal/grid laser at baseline and month 3 (group 3, 42 patients).

Main Outcome Measures

The primary end point was the change from baseline in best-corrected visual acuity (BCVA) at month 6.

Results

At month 6, the mean gain in BCVA was significantly greater in group 1 (+7.24 letters, P = 0.01, analysis of variance) compared with group 2 (−0.43 letters), and group 3 (+3.80 letters) was not statistically different from groups 1 or 2. For patients with data available at 6 months, improvement of 3 lines or more occurred in 8 of 37 (22 % ) in group 1 compared with 0 of 38 (0 % ) in group 2 (P = 0.002, Fisher exact test) and 3 of 40 (8 % ) in group 3. Excess foveal thickness was reduced by 50 % , 33 % , and 45 % in groups 1, 2, and 3, respectively.

Conclusions

During a span of 6 months, ranibizumab injections by the current protocol had a significantly better visual outcome than focal/grid laser treatment in patients with DME.

Financial Disclosure(s)

Proprietary or commercial disclosure may be found after the references.